Not Yet Recruiting NA INTERVENTIONAL 2-arm
NCT06773221
The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
A Key Therapeutic System for Reversing MAFLD-related Cirrhosis: a Randomized Double-blind Controlled Trial on the Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis
Sponsor: Beijing Ditan Hospital
Interventions
Chiglitazar 64mg Placebo
Updated 1 time since 2025 Last updated: Jan 13, 2025 Started: Feb 5, 2025 Primary completion: Jan 31, 2028 Completion: Jun 30, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on Compensated Liver Cirrhosis and Metabolic Dysfunction Associated Fatty Liver Disease, this trial is actively recruiting participants. The trial is conducted by Beijing Ditan Hospital and has accumulated 1 data snapshot since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
1 version recorded Not Yet Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Beijing Ditan Hospital
- Beijing Friendship Hospital
- Beijing YouAn Hospital
- Peking University People's Hospital
Data source: Beijing Friendship Hospital
For direct contact, visit the study record on ClinicalTrials.gov .